Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-29

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will characterize tau tracer retention by Positron Emission Tomography (PET) as a function of amyloid levels transversally and longitudinally.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

NCT02685969

Alzheimer's Disease

RECRUITING

Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants

NCT02187627

Alzheimer's Disease, Healthy Volunteer

COMPLETED PHASE1

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

NCT05456503

Frontotemporal Lobar Degeneration Alzheimer Disease Cognitively Normal

RECRUITING PHASE3

Imaging Tau in Alzheimer's Disease and Normal Aging

NCT03373604

Alzheimer Disease

COMPLETED PHASE2

Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults

NCT03129269

Frail Elderly

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CROSS-SECTIONAL OBJECTIVES

* To measure 18F-RO6958948 retention in selected participants of ALFA-related studies as a function of amyloid levels.
* To study the relation between 18F-RO6958948 retention and amyloid levels.
* To characterize imaging correlates as a function of tau and amyloid levels.
* To study the role of tau retention on cognitive performance.
* To define predictors of tau retention.

LONGITUDINAL OBJECTIVES

* To measure tau accumulation and spreading in participants of the ALFA-related studies of BBRC as a function of baseline amyloid levels.
* To study the dynamic relation between tau spreading and amyloid levels longitudinally.
* To define predictors of tau spreading.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PET

Group Type EXPERIMENTAL

Positron emission tomography with 18F-RO6958948

Intervention Type PROCEDURE

tau PET ()

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Positron emission tomography with 18F-RO6958948

tau PET ()

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. To sign the study informed consent form approved by the corresponding authorities.
2. Men and women that have participated in a BBRC-sponsored study, including the ALFA project (STUDY 45-65 FPM/2012), the ALFA+ cohort study (ALFA - FPM - 0311), the ALFA cognition study (ALFAcognition/BBRC2017) or the BarcelonaBeta Dementia Prevention Research Clinic study (BBRC-DemPrev-2018).
3. Participants with an available cerebral MRI within the last 12 months not suggestive of radiological incidental findings constituting an exclusion criterion.
4. Known cognitive status based on the cognitive workup of the BBRC-sponsored studies specified above. Cognitive status should have been determined within the last 12 months.
5. Known AB and tau status.
6. Good knowledge of the language and being literate.
7. Female participants should be post-menopausal or present a negative pregnancy test at the moment of PET acquisition.

Exclusion Criteria

1. Presence of clinically relevant psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) criteria: major depressive disorder, generalized anxiety disorder, schizophrenia and bipolar disorder, as assessed in the BBRC-sponsored studies specified above.
2. Participants with visual and/or hearing impairment.
3. History of encephalitis, ictus or seizures excluding feverish convulsions during childhood, as assessed in the BBRC-sponsored studies specified above.
4. Severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumour (metastasis/brain cancer) as verified by MRI.
5. Previous participation in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and/or administration of a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study.
6. Clinically relevant renal or hepatic insufficiency.
7. Any other clinically important condition that may jeopardize the study or be dangerous for the participant.
8. Active drug or alcohol abuse, as assessed in the BBRC-sponsored studies specified above.
9. Previous intolerance to PET studies or known hypersensitivity to 18F-RO6958948.
10. Being pregnant or breast-feeding.

Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes